Tagged Articles

Endo 6 articles

Endo faces more testosterone side effects trials

Endo Pharmaceutical may have gotten a pass on the latest testosterone side effects trial, but its problems are far from resolved. The drug company faces nearly 1,300 lawsuits involving its testosterone replacement therapy Testim, as well as other testosterone products it markets, in state and federal courts. Endo faced the third trial in a class action lawsuit against several manufacturers of testosterone treatments over claims that the drugs caused cardiovascular side effects including heart attacks, strokes, blood clots and death. The first two trials were waged against AbbVie Inc., maker of the blockbuster testosterone treatment AndroGel, and resulted in verdicts ... Read More

Opioid users file lawsuit against drug makers

Opioid users are pushing back against the manufacturers of the powerful and highly addictive painkillers, suing Actavis, Endo, Johnson & Johnson, Purdue, Teva and others in Arkansas federal court, claiming the drug companies were more focused on making profits than on public health, Law360 reports. They say the opioid makers encouraged doctors to prescribe the drugs while downplaying the addiction and dependence risks associated with use, which in turn contributed to the national opioid epidemic. The same drug companies are currently under investigation by several attorneys general representing states across the country. They also face similar probes with counties and cities ... Read More

Sales of testosterone nasal spray to be discontinued in U.S.

Pharmaceutical company Endo is terminating its agreement with Acerus Pharmaceuticals Corporation to market the nasal testosterone treatment NATESTO in the United States, effective June 30, 2016. NATESTO was approved in May 2014 and is the first and only testosterone nasal spray gel sold in the U.S. for the treatment of hypogonadism, a condition in which men do not produce enough testosterone due to injury or disease. The gel is available as a metered dose pump containing 60 actuations. Each pump delivers 5.5mg of testosterone in 0.122g gel. “While we are disappointed with Endo’s previously announced strategic business decision to realign their U.S. ... Read More

Bard ordered to pay $3.6 million over defective transvaginal mesh

C.R. Bard was slapped with a $3.6 million verdict in the first lawsuit to go to trial involving the medical device manufacturer’s allegedly defective transvaginal mesh. The ruling comes just months after the company agreed to settle thousands of other lawsuits from women who claim to have been injured by the transvagainal mesh. The jury had awarded the plaintiff in the case $5.5 million in damages, but the court slashed the award to $3.6 million after finding some fault with the doctor who had implanted the plaintiff with the company’s Avaulta transvaginal mesh. Transvaginal mesh, also known as bladder sling, ... Read More

Judge ups Endo whistleblower’s FCA award to $33.6 million

A former Lidoderm sales representative for Endo Health Solutions and its subsidiary Endo Pharmaceuticals will receive a $33.6-million payout as her share of $172-million settlement she was instrumental in bringing about with her whistleblower lawsuit. Peggy Ryan sued her former employer in 2005 under the False Claims Act, alleging the company misbranded Lidoderm, a prescription drug for shingles pain, and pushed it for purposes not approved by the U.S. Food and Drug Administration (FDA). In her whistleblower complaint, Ms. Ryan alleged that her superiors at Endo urged her to promote Lidoderm for off-label purposes by goading physicians to talk with ... Read More

FDA approves Endo’s new Aveed testosterone injections

U.S. drug regulators gave Irish drugmaker Endo Pharmaceuticals the green light to manufacture and market its long-lasting testosterone injection Aveed in the United States, making it the latest addition to a growing list of testosterone-replacement therapies drug companies are aggressively marketing to men in the U.S. and other countries. Endo Pharmaceuticals said the U.S. Food and Drug Administration (FDA) approved Aveed to treat men with hypogonadism, commonly referred to as “low testosterone” or “low T,” a condition in which the body produces lower than normal levels of the hormone. Men with abnormally low testosterone levels often experience declines in muscle, ... Read More